RMRK
8.6.2021 15:32:07 CEST | Business Wire | Press release
RMRK , an advanced NFT protocol project, announced today that it raised 6 million USD to build the standard cross-chain NFT infrastructure in the Polkadot and Kusama ecosystem. Investors such as D1 Ventures , YBB , PAKA , DFG , and others are all betting on NFTs 2.0 as presented by RMRK.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005768/en/
“NFTs right now are digital-dust-gathering assets, mainly overpriced digital pictures that you keep in your digital wallet until the next NFT hype wave hits.” says Bruno Škvorc, project founder and Web3 Foundation alum. “We believe that they’re meant for much more than that. NFTs can have long lasting liquidity by being upgradable, nestable within other NFTs, by being able to react to people reacting to them with emotes, and by being democratically governed through fractional ownership!”
By launching a gamified “initial collectible offering” called Kanaria on Kusama even without smart contracts, the RMRK team has pioneered the NFT-crowdfunding approach which netted them a total of 2 million USD in limited edition egg-nft sales. All egg buyers will also be entitled to a fairdrop of the coming $RMRK token. The remaining 4 million were raised directly from investors based on the vision of NFTs 2.0.
NFTs 2.0
RMRK is developing new standards to expand what NFTs can do:
● NFTs that can own other NFTs
● NFTs that can listen to commands or issue them to their children
● NFTs as DAOs that can, through fractional ownership, be controlled by a group
● NFTs that can react to emotion with conditional rendering logic (send 50 rocket emoji to a picture of a moon, and it can show you a moonbase)
● NFTs that can have multiple resources at once (mint an e-book with an audio version, a PDF file, and a high resolution cover - the environment it’s loaded in decides which part to load automatically).
With these “art legos” in place, RMRK has created an NFT operating system that makes possible NFT projects of arbitrary complexity .
Powerful Partnerships
This potential of art legos was recognized by key players in the Kusama and Polkadot ecosystem, as documented on RMRK’s official blog . Rather than crowd the already crowded parachain space, RMRK has opted to add their technology to other chains instead - the project’s very first runtime-based deployment will be with Unique Network , a dedicated NFT parachain project in the Kusama and Polkadot ecosystem.
With RMRK’s logic coming into the runtime functionality of several partner chains, the RMRK standards for NFTs 2.0 are poised to become the first shared-runtime environment in the Polkadot ecosystem, allowing for seamless teleportation of non fungible assets to and from any supported chain, natively, and at almost zero cost.
You can learn more about RMRK at rmrk.app , and you can play around with their official minting and trading UI for NFTs called Singular on singular.rmrk.app . Reach out to the team at hello@rmrk.app , on Telegram , or on Twitter , and read their blog on Subsocial .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005768/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
